EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel Therapeutic Development for Nasopharyngeal Carcinoma

Jongwoo Kim iD, Yunjoo Lee, Seoin Kim, Jong Chul Park iD

Current Oncology · 2025

DOI: 10.3390/curroncol32090479 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2025. Verfasst von Jongwoo Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: MetroWest Medical Center, Framingham, MA 01702, USA. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nasopharyngeal carcinoma (NPC) is a rare malignancy with a distinct epidemiological pattern and is most often associated with Epstein–Barr virus (EBV). EBV plays a critical role in NPC pathogenesis, with viral proteins driving oncogenesis by altering immune regulation, apoptosis, and tumor progression. The unique molecular landscape of NPC presents both challenges and opportunities for therapeutic development, particularly in the recurrent and metastatic (R/M) setting, where treatment resistance remains a major hurdle. While platinum-based chemotherapy has traditionally been the standard of care for R/M NPC, immune checkpoint inhibitors (ICIs) have emerged as a key component of treatment. However, both intrinsic and acquired resistance to PD-1/PD-L1 blockade underscore the need for alternative strategies, including modulation of alternative immune checkpoints and simultaneous engagement of non-redundant pathways to enhance responses and durability. Leveraging EBV-driven biology, emerging immunotherapeutic approaches, such as EBV-specific adoptive cellular therapies and therapeutic vaccines, aim to induce durable immunity to viral proteins. Additionally, targeted therapies including receptor tyrosine kinase inhibitors, epigenetic modulators, and antibody–drug conjugates are redefining precision medicine by selectively delivering cytotoxic agents to tumors. With growing insights into the biology of NPC and evolving therapeutics, the integration of immunotherapy, targeted agents, and biomarker-driven strategies is poised to transform NPC treatment, emphasizing biology-driven, multimodal approaches to optimize patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsHumansImmune Checkpoint InhibitorsHerpesvirus 4, HumanImmunotherapy

Stichwörter der Autor:innen

adaptive cell therapyimmunotherapynasopharyngeal carcinomatherapeutic vaccine

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • MetroWest Medical Center, Framingham, MA 01702, USA.
  • Medicine-Hematology and Medical Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • Ragon Institute, Cambridge, MA 02139, USA.

ORCID-Profile: Jongwoo Kim, Jong Chul Park

Zitieren

APA

Kim, J., Lee, Y., Kim, S., & Park, J. C. (2025). Novel Therapeutic Development for Nasopharyngeal Carcinoma. Current Oncology. https://doi.org/10.3390/curroncol32090479

Vancouver

Kim J, Lee Y, Kim S, Park JC. Novel Therapeutic Development for Nasopharyngeal Carcinoma. Current Oncology. 2025. doi:10.3390/curroncol32090479

BibTeX
@article{Kim2025,
  author = {Kim, Jongwoo and Lee, Yunjoo and Kim, Seoin and Park, Jong Chul},
  title = {Novel Therapeutic Development for Nasopharyngeal Carcinoma},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32090479}
}
Kostenlos starten →